Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CRCorbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NASDAQ · Currency in USD
$4.05 ▼ -0.08 (-1.94%)
At close: Oct 23, 4:00 PM ET. Market closed.
$4.03 ▼ -0.02 (-0.49%)
After hours: Oct 23, 7:51 PM ET

Summary

Previous Close
$4.13
Open
$4.08
Day's Range
$3.94 – $4.08
52 Week Range
$3.93 – $18.11
Volume
372,540
Avg. Volume
726,140
Market Cap
$78.33M
Beta (5Y Monthly)
2.63
PE Ratio (TTM)
--
EPS (TTM)
-$5.25
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$33.67

Profile: Corbus Pharmaceuticals Holdings, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
36
CEO
Yuval Cohen

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$1.21 · Revenue est. $2.00M
DateEst.Actual
Aug 6, 2026-$1.26-$1.81Miss
May 12, 2026-$1.26-$1.23Beat
Mar 9, 2026-$1.78-$1.25Beat
Nov 12, 2025-$1.80-$1.90Miss
Aug 5, 2025-$1.55-$1.44Beat
May 6, 2025-$1.26-$1.39Miss

Analyst view

Consensus price target
$33.67 ▲ +731.4%
Range $33.00 – $35.00
Rating: Buy
Buy 88% · Hold 13% · Sell 0%

Get free alerts on CRBP and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.